Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differential effects on CLL cell survival exerted by different microenvironmental elements.

P Ghia1, P Circosta, C Scielzo

  • 1Department of Oncology, Università Vita-Salute, San Raffaele, Milano, Italy. ghia.paolo@hrs.it

Current Topics in Microbiology and Immunology
|December 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

Journal of hematology & oncology·2026
Same author

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.

American journal of hematology·2024
Same author

Collateral presence and extent do not predict myocardial viability and ischemia in chronic total occlusions: A stress-CMR study.

International journal of cardiology·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Chronic lymphocytic leukemia (CLL) cells gain survival advantages from their microenvironment. T lymphocytes offer short-term support, while stromal cells provide crucial long-term survival benefits for leukemic B cells.

Area of Science:

  • Hematology
  • Immunology
  • Cell Biology

Background:

  • The tumor microenvironment significantly influences cancer cell survival and proliferation.
  • Chronic lymphocytic leukemia (CLL) cells accumulate within specific microenvironmental niches.
  • Understanding the cellular interactions within the CLL microenvironment is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the differential support provided by microenvironmental components to CLL cells.
  • To determine the distinct roles of stromal cells and T lymphocytes in sustaining leukemic B cell survival.
  • To analyze the impact of soluble factors like IL-4 and sCD40L on CLL cell viability and chemoattracting capacity.

Main Methods:

  • Purified CLL cells were cultured in vitro.

Related Experiment Videos

  • Cultures included varying combinations of accessory cells (stromal cells, autologous T lymphocytes) and soluble molecules (IL-4, sCD40L).
  • Leukemic cell viability and chemoattracting capacity were assessed to evaluate microenvironmental support.
  • Main Results:

    • Both T lymphocytes and stromal cells contribute to leukemic B cell survival.
    • T lymphocytes provide short-term support to CLL cells.
    • Stromal cells offer sustained, long-term support for CLL cell survival.

    Conclusions:

    • The CLL microenvironment differentially supports leukemic cell survival based on cell type and duration of interaction.
    • Stromal cells are key players in providing long-term survival signals to CLL cells.
    • Targeting stromal cell-mediated support could be a therapeutic strategy for CLL.